252 related articles for article (PubMed ID: 2334465)
1. General pharmacology of recombinant human tumor necrosis factor. 2nd communication: effects on central nervous system functions.
Kurumiya S; Miura Y; Nakatsuji K; Dodo M; Hori M; Ito T
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):225-31. PubMed ID: 2334465
[TBL] [Abstract][Full Text] [Related]
2. General pharmacology of recombinant human basic fibroblast growth factor.
Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
[TBL] [Abstract][Full Text] [Related]
3. General pharmacology of recombinant human tumor necrosis factor. 1st communication: effects on cardiovascular, gastrointestinal, renal and blood functions.
Nakatsuji K; Kii Y; Fujitani B; Ito T
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):218-25. PubMed ID: 2334464
[TBL] [Abstract][Full Text] [Related]
4. [Effects of suloctidil on the central and peripheral nervous systems].
Nishi H; Watanabe T; Mori M
Nihon Yakurigaku Zasshi; 1983 Sep; 82(3):191-212. PubMed ID: 6319248
[TBL] [Abstract][Full Text] [Related]
5. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
Hirotsu I; Kihara T; Nakamura S; Hattori Y; Hatta M; Kitakaze Y; Takahama K; Hashimoto Y; Miyata T; Ishihara T
Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
[TBL] [Abstract][Full Text] [Related]
6. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
[TBL] [Abstract][Full Text] [Related]
7. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system.
Murata T; Sakaya S; Hoshino T; Umetsu T; Hirano T; Nishio S
Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742
[TBL] [Abstract][Full Text] [Related]
8. General pharmacology of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate. 1st communication: effects on the central nervous system.
Saito T; Fukuda T; Sukamoto T; Yoshidomi M; Morimoto Y; Shimohara K; Ito K
Arzneimittelforschung; 1988 Jan; 38(1):66-9. PubMed ID: 2896509
[TBL] [Abstract][Full Text] [Related]
9. General pharmacology of the new quinolone antibacterial agent levofloxacin.
Takasuna K; Kasai Y; Usui C; Takahashi M; Hirohashi M; Tamura K; Takayama S
Arzneimittelforschung; 1992 Mar; 43(3A):408-18. PubMed ID: 1622443
[TBL] [Abstract][Full Text] [Related]
10. General pharmacological properties of the new vasodilator flosequinan.
Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological studies of mabuterol, a new selective beta 2-stimulant. III: Effects on the central nervous system, striated muscle and carbohydrate and lipid metabolism.
Osada E; Sakaya S; Sanai K; Seri K
Arzneimittelforschung; 1984; 34(11A):1652-8. PubMed ID: 6152158
[TBL] [Abstract][Full Text] [Related]
12. General pharmacological properties of muroctasin.
Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
[TBL] [Abstract][Full Text] [Related]
13. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
14. Behavioral characterization of the new potent nonselective dopamine agonist pergolide.
Helton DR; Modlin DL; Williams PD
Arzneimittelforschung; 1992 Jul; 42(7):885-90. PubMed ID: 1418051
[TBL] [Abstract][Full Text] [Related]
15. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
[TBL] [Abstract][Full Text] [Related]
16. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and uracil. I: Pharmacological analysis of the combined effect of FT and uracil.
Yamamoto J; Toide K; Haruno A; Yoshimura Y; Unemi N
Arzneimittelforschung; 1981; 31(8):1268-78. PubMed ID: 6794578
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems.
Hirohashi M; Takasuna K; Kasai Y; Usui C; Kojima H
Arzneimittelforschung; 1991 Jan; 41(1):19-24. PubMed ID: 1675569
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of amezinium, a novel antihypotensive drug. VI. Effect on central nervous functions.
Teschendorf HJ; Kretzschmar R; Kreiskott H; Weifenbach H
Arzneimittelforschung; 1981; 31(9a):1580-8. PubMed ID: 7197973
[TBL] [Abstract][Full Text] [Related]
19. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
[TBL] [Abstract][Full Text] [Related]
20. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
Matsuno Y; Hori H; Oka M; Nakamura H; Ito T; Kadokawa T
Arzneimittelforschung; 1986; 36(1):62-8. PubMed ID: 3513778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
